Udayam Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 21-06-2024
- Paid Up Capital ₹ 1.00 M
as on 21-06-2024
- Company Age 11 Year, 3 Months
- Last Filing with ROC 31 Mar 2018
- Open Charges ₹ 6.50 M
as on 21-06-2024
- Revenue -1.74%
(FY 2018)
- Profit 9.01%
(FY 2018)
- Ebitda -281.95%
(FY 2018)
- Net Worth 13.21%
(FY 2018)
- Total Assets -14.11%
(FY 2018)
About Udayam Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹6.50 M.
Nangamangalam Vasantha and Nangamangalam Giridharan serve as directors at the Company.
- CIN/LLPIN
U74900TN2013PTC092755
- Company No.
092755
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Aug 2013
- Date of AGM
30 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Tiruvallur, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Udayam Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nangamangalam Vasantha  | Director | 26-Sep-2018 | Current |
| Nangamangalam Giridharan | Director | 28-Jan-2016 | Current |
Financial Performance and Corporate Structure Insights of Udayam Pharmaceuticals.
Udayam Pharmaceuticals Private Limited, for the financial year ended 2018, experienced Minor drop in revenue, with a 1.74% decrease. The company also saw a slight improvement in profitability, with a 9.01% increase in profit. The company's net worth Soared by an impressive increase of 13.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Udayam Pharmaceuticals?
In 2018, Udayam Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Teja Pharma Private LimitedActive 13 years 9 monthsNangamangalam Vasantha and Nangamangalam Giridharan are mutual person
- Annamalayar Medicals Private LimitedActive 18 years 6 months
Nangamangalam Giridharan is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
City Union Bank Limited Creation Date: 29 Apr 2016 | ₹6.50 M | Open |
How Many Employees Work at Udayam Pharmaceuticals?
Unlock and access historical data on people associated with Udayam Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Udayam Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Udayam Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
